Small molecule · Inhibitor of PIK3CA H1047R mutant (PIK3CA) · developed by Cogent Biosciences
CGT6297 is an orally bioavailable allosteric inhibitor of mutant PIK3CA, selectively targeting the H1047R mutation while sparing wild-type PI3Ka. It inhibits PI3K/Akt/mTOR pathway activation, inducing apoptosis and growth inhibition in PIK3CA-mutant tumors. It is studied in advanced solid tumors, endometrial cancer, and HR-positive/HER2-negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07383506 | Phase 1 | PIK3CA Mutations | Recruiting | COGT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors, AdultEndometrial CancerHER2-low Breast CancerHR Positive/HER-2 Negative Breast CancerPIK3CA Mutations
Updated Oct 3, 2026. Something wrong or missing? Report it on the COGT page.
See COGT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
COGT catalysts and pipeline →